Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $13.3 million.

  • Entrada Therapeutics' Accumulated Expenses rose 15.88% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 15.88%. This contributed to the annual value of $13.3 million for FY2024, which is 17.82% up from last year.
  • Entrada Therapeutics' Accumulated Expenses amounted to $13.3 million in FY2024, which was up 17.82% from $11.3 million recorded in FY2023.
  • Over the past 5 years, Entrada Therapeutics' Accumulated Expenses peaked at $13.3 million during FY2024, and registered a low of $7.6 million during FY2022.
  • Over the past 3 years, Entrada Therapeutics' median Accumulated Expenses value was $11.3 million (recorded in 2023), while the average stood at $10.7 million.
  • Data for Entrada Therapeutics' Accumulated Expenses shows a peak YoY skyrocketed of 49.49% (in 2023) over the last 5 years.
  • Entrada Therapeutics' Accumulated Expenses (Yearly) stood at $7.6 million in 2022, then spiked by 49.49% to $11.3 million in 2023, then rose by 17.82% to $13.3 million in 2024.